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Abstract
Background
Prevalence of erectile dysfunction (ED) in male 
survivors of cancer across cancer types has not 
been systematically analysed. 
Aim
To estimate the prevalence of ED in all types of 
cancer and identify characteristics associated with 
ED in survivors of cancer.
Design and setting
Systematic review and meta-analysis (MA) of 
cross-sectional studies.
Method
MEDLINE, CINAHL, PsycINFO, and EMBASE 
were searched, targeting reports published from 
inception to 1 February 2020. All retrospective 
or prospective studies reporting prevalence of 
ED in male patients with cancer and using a 
validated tool for detection of ED were included. 
A random-effects MA model was used to pool 
prevalence of ED as absolute estimates at three 
different stages, that is, ‘healthy’, ‘at diagnosis’, 
and ‘after treatment’. A univariate MA regression 
including the three-level group variable as the 
only independent variable was used to assess 
the difference in ED prevalence across the three 
groups. Further MAs were conducted for studies 
involving patients at diagnosis and after treatment, 
and statistical inferences were made with setting 
for multiple testing controlling for a false discovery 
rate (FDR) <0.05.
Results
In total, 1301 studies were assessed for inclusion. 
Of these, 141 were potentially eligible and 
subsequently scrutinised in full text. Finally, 
43 studies were included with a total of 13 148 
participants. Overall, pooled data of the included 
studies showed an ED prevalence of 40.72% 
(95% confidence interval [CI] = 31.80 to 50.29) in 
patients with cancer, with prevalences of 28.60% 
(95% CI = 12.10 to 53.83) at time of diagnosis and 
42.70% (95% CI = 32.97 to 53.03) after treatment, 
with significant difference between these two 
stages and across cancer locations, controlling for 
an FDR <0.05. 
Conclusion
Erectile dysfunction was particularly high in male 
survivors of cancer and was associated with 
cancer treatment, cancer site, and age. 
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INTRODUCTION
Cancers located in the pelvic region 
represent >25% of all newly diagnosed 
cancers worldwide in males.1 This 
localisation of cancer has also been 
associated with long-term severe sexual 
dysfunction in at least half of all patients.2 
Erectile dysfunction (ED), the inability to 
obtain or maintain an erection that allows 
for sexual intercourse, is one of the most 
distressing consequences of cancer 
diagnosis and treatment in males.3 
Erectile dysfunction has a complex 
aetiology influenced by cancer in both direct 
and indirect ways. Males diagnosed with 
prostate cancer, the second most common 
type of cancer (except for non-melanoma 
skin cancer) in males,1 are expected to 
have the same risk factors (cardiovascular 
disease and metabolic disorders) for ED 
when compared with cancer-free age-
matched males. However, risks for ED are 
increased given a higher incidence of lower 
urinary tract symptoms and psychological 
distress in males with prostate cancer.4,5 
Indirect pathways, mostly associated with 
cancer treatment modalities (surgery, 
chemo- and radiotherapy, and hormone 
treatment) seem to be the most common 
causes.6,7 
Moreover, few males are able to achieve 
a normal erection following pelvic surgery, 
with studies noting that, even in males 
with excellent baseline erections, <25% 
retained or recovered the erection quality 
as before treatment. Pelvic surgeries 
most associated with ED are radical 
prostatectomy, radical cystectomy, and low 
anterior or abdominoperineal resections.8 
Furthermore, the results from a 12-year 
follow-up study showed that 84% and 80%, 
respectively, of males with prostate cancer 
who had radical prostatectomy or were 
under active surveillance reported ED, 
compared with 43% in the matched control 
group.9 Similar results have been reported 
for males who had treatment for other types 
of pelvic cancer, such as anal, rectal, or 
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bladder cancer.10–15 However, it is noteworthy 
that ED is not only prevalent in males with 
pelvic cancers but may also be the result of 
intensive chemo- or radiotherapy, causing 
hypogonadism or pelvic nerve damage. 
Studies have shown ED also after lung 
cancer, haematological malignancies, and 
head and neck tumours.16–18 
Sexuality and intimacy are important 
aspects of quality of life and may also 
reduce some of the psychosocial distress 
associated with the cancer diagnosis. 
In this light it has been reported that 
maintaining normal sexual function in 
males with cancer can be important to 
help relieve suffering.19,20 Given the growing 
incidence of cancer globally and new 
therapeutic modalities that are prolonging 
life expectancy in survivors of cancer, 
questions of quality of life post-diagnosis 
and treatment are increasingly relevant. 
However, studies on ED in survivors of 
cancer are rare, and mostly focused on 
cancer localisations in the pelvic region, 
making prevalence estimates of ED in 
survivors of cancer rare. Providing pooled 
estimates of ED prevalence as well as 
its associations should provide important 
information not only on the scale of the 
issue but also help clinicians working 
with survivors of cancer to easily identify 
patients who are at risk of ED, and provide 
comprehensive cancer care associated 
with long-term quality of life.
Therefore, the aim of this systematic 
review and meta-analysis (MA) was to 
examine the available studies and provide 
pooled estimates for ED prevalence in 
relation to all cancer sites and identify 
characteristics associated with ED in 
survivors of cancer. To the authors’ 
knowledge, this is the first study of its kind. 
METHOD
Search strategy
Four electronic databases, MEDLINE, 
CINAHL, PsycINFO, and EMBASE, were 
searched, targeting reports published from 
database inception to 1 February 2020. 
Terms included in the search strategy are 
reported in Supplementary Table S1. 
The references of retrieved articles, 
together with the proceedings of relevant 
conferences, were hand-searched in order 
to identify other potentially eligible studies 
for inclusion that were missed by the initial 
search, or any unpublished data. 
The literature search, assessment of 
inclusion and exclusion criteria, quality 
of studies, and extraction of data were 
independently undertaken and verified by 
the first and second authors. The results 
were then compared and, in case of 
discrepancies, a consensus was reached 
with the involvement of the third author. 
There was no language restriction.
Type of studies, inclusion and exclusion 
criteria
All retrospective or prospective studies 
reporting the prevalence of ED in male 
patients with cancer and using a validated 
tool for ED detection, for example, the 
International Index of Erectile Function 
(IIEF-5), were included in this review. 
Studies that did not meet the inclusion 
criteria were excluded.
Types of outcome measures
All outcomes were defined before 
conducting the literature search. The 
primary outcome was the prevalence of ED 
across relevant cancer treatment stages, 
that is, ‘healthy’, ‘at diagnosis’, and ‘after 
treatment’.
Data extraction and statistical analyses
Descriptive tables for population and 
study characteristics were generated 
for all included studies. The first author, 
publication year, country of investigators, 
sample size, age, method of assessment of 
ED, and cancer type and site were recorded. 
Furthermore, number of patients with ED 
among case and control groups, body mass 
index, hormonal levels, smoking status, 
and presence of hypertension, diabetes, 
dyslipidaemia, and cardiovascular diseases 
were recorded. All statistical analyses 
based on these data were performed using 
R (version 3.6.1). 
For the included studies at the three 
different stages, that is, 'healthy', 'at 
diagnosis', and 'after treatment', a random-
effects MA model with the between-
How this fits in 
In male survivors of cancer, normal sexual 
function may be disturbed owing to the 
occurrence of erectile dysfunction (ED). 
The present systematic review and meta-
analysis reports 40.72% prevalence of ED 
in survivors of cancer, with the prevalence 
being somewhat higher (42.70%) in studies 
that focused on reporting prevalence after 
cancer treatment. The reasons for high 
occurrence of ED in male survivors of 
cancer is multimodal and includes a variety 
of factors, such as psychological and 
physical ones. Clinicians should be aware 
that ED has a large effect on the quality of 
life and mental health of male survivors of 
cancer.
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study heterogeneity parameter estimated 
by DerSimonian–Laird (DL) method21 
was used to pool the prevalence of ED 
as absolute estimates (%) with their 95% 
confidence intervals (CIs) for each stage. 
A univariate MA regression including the 
three-level group variable for healthy/at 
diagnosis/after treatment stages as the 
only independent variable was used to 
assess the difference in ED prevalence 
across the three stages. A scatter plot 
with point and CI estimates of prevalence 
of ED across three different groups of 
patients is illustrated. Publication bias was 
assessed by a visual inspection of funnel 
plots and calculating the Egger bias test.22 
The authors planned to apply the trim 
and fill analysis23 for overcoming possible 
publication bias (P<0.10).
Further MA were conducted for the 
40 studies only involving patients at 
diagnosis and after treatment, that is, 
excluding healthy control. Graphical 
comparisons of the prevalence of ED across 
these two stages of cancer treatment were 
given by a classic forest plot. Heterogeneity 
across these 40 studies involving the two 
cancer treatment stages was assessed by 
the I 2 metric and taking, as measure of 
high heterogeneity, an I 2 >50% or P<0.05 
for testing the c2-distributed Q statistic 
for between-studies heterogeneity (a 
high value of Q would result in a high 
value of I 2 since I 2 = [Q-K+1]/Q where K 
is the number of studies).24 In case of 
high ED-prevalence heterogeneity and 
having at least 10 studies for the outcome, 
the authors used stage, continent, mean 
age, age range, age standard deviation, 
method of ED assessment, cancer site, 
proportion of patients that underwent 
radiotherapy, proportion of patients with 
diabetes, and proportion of patients that 
underwent chemotherapy as possible 
predictors for MA regression analyses. 
The plots of study count distribution for 
each of the above moderators across their 
observed values are given. A univariate 
MA regression model for each moderator 
was fitted. The stage predictor as well as 
the significant moderators screened out by 
these univariate MA regression analyses 
were used as potential predictors to fit 
a multiple MA regression with manual 
variable selection procedure applied. 
The conclusions by the final multiple MA 
regression model were drawn with multiple 
testing concern by controlling for a false 
discovery rate (FDR).25 Back-transformed 
estimated prevalence values of ED with 
95% CI for studies with different levels of 
predictor variables in the final multiple MA 
regression model are given. 
For all MA regression, the authors applied 
the logit transformation to the observed 
prevalence across primary studies to make 
the transformed prevalence follow a normal 
distribution, and the MA regression analysis 
was based on the transformed scale.
Assessment of study quality
Study quality was assessed by two 
investigators (first and third authors) using 
the Newcastle–Ottawa Scale (NOS).26,27 
This scale has been adapted from the 
Newcastle–Ottawa Quality Assessment 
Scale for cohort studies to perform a quality 
assessment of cross-sectional studies 
for the systematic review. A third reviewer 
was available for mediation (thirteenth 
author). The NOS assigns a maximum of 9 
Figure 1. Comparisons of prevalence of ED among 
patients with cancer and healthy control. Pooled 
prevalence of ED represented by red square and the 
corresponding CIs shown in red extending line (blue 
circles are centred at the prevalence of ED reported in 
each of the included primary studies with circle size 
proportional to sample size of each primary study).  
ED = erectile dysfunction.
Table 1. Study counts and pooled prevalence of ED across three 
stages 
 Stage
Counts/prevalence Healthy control At diagnosis After treatment Total
Study count, n 3 5 35 43
Pooled number of patients 250 782 2794 3826 
with ED, n
Pooled sample size, n 1240 2403 9505 13 148 
Pooled prevalence (95% CI) 0.1370 (0.0394 to 0.2861 (0.1229 to  0.4269a (0.3311 to — 
 0.3808) 0.5340) 0.5286)
aThe ED prevalence among patients with cancer ‘after treatment’ was statistically significantly different from that of 
‘healthy control’ at level 0.05 ( P = 0.0322; this can also be seen by the fact that the point estimate of ED prevalence 
for ‘healthy control’, 0.1370, is not included in the 95% CI of ED prevalence for patients with cancer after treatment). 
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points based on three quality parameters: 
selection, comparability, and outcome.
RESULTS
The electronic search yielded 1301 studies, 
after de-duplication, that were assessed 
for inclusion in the review. Of these, 141 
were potentially eligible and subsequently 
scrutinised in full text (see Supplementary 
Figure S1).
Excluded studies
Among the relevant studies, 98 failed 
to meet the inclusion criteria and were 
excluded from this review. Of these, 37 used 
no validated tools for ED assessment, 
36 had no useful data on ED prevalence, 
18 were longitudinal studies, four had no 
data on the association between ED and 
cancer, and three were double publications.
Included studies
The 43 studies that were included, 
36 prospective and 7 retrospective, 
contained a total of 13 148 participants.28–59 
The majority of the studies (n = 25) were 
conducted in Europe, with those remaining 
in North America (n = 6), Asia (n = 6), the 
Middle East (n = 5), and Oceania (n = 1). The 
most affected cancer sites were prostate 
and rectum (n = 12 studies, respectively), 
testis (n = 6), haematological (n = 5), 
multiple (n = 3), colorectal (n = 2), and penis, 
colon, and anus (n = 1 each).
According to NOS, the median quality 
of the studies was 4.97 (range 3–7), 
indicating an overall good quality of studies 
(Supplementary Table S2). In particular, 
the majority of the studies (n = 18) scored 
5, followed by 11 studies with 4. Only three 
studies scored 3 while six and five studies 
scored 6 and 7, respectively.
Meta-analysis on prevalence of ED across 
three stages: healthy, at diagnosis, and 
after treatment
Distribution of study counts and the 
corresponding pooled prevalence of ED at 
the three different stages are shown in 
Table 1. The pooled prevalence of ED at 
the ‘after treatment’ stage was statistically 
significantly different from that of ‘healthy 
control’ by the univariate MA regression 
analysis with dummy variables for stage 
(P = 0.0322).
The pooled prevalence of these three 
groups is illustrated in Figure 1 to compare 
prevalence of ED among patients in the 
two cancer treatment stages with that of 
‘healthy control’ individuals. 
Small study effect (including publication 
bias) was not found among the included 
studies and the trim and fill analysis did 
not modify the results. Figure 2 shows the 
funnel plot, with non-significant Egger’s 
test result for funnel plot asymmetry 
(P = 0.4418).
Meta-analysis on prevalence of ED 
across the two cancer treatment stages: 
at diagnosis and after treatment 
Pooling data of the 40 studies of patients 
with cancer only, that is, excluding three 
studies of healthy controls, an overall 
prevalence of 40.72% (95% CI = 31.80% to 
50.29%) was found, with a prevalence of 
28.60% (95% CI = 12.10% to 53.83%) at time 
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Figure 2. Funnel plot. 
Table 2. Study counts of the 10 possible predictors for ED prevalence 
and P-value for the uni-predictor (or smallest P-value for the uni-
predictor dummy variables) in the univariate MA regression analysis
Predictor Study count, n Coefficient estimate 95% CI P-value
Stage 40 0.6210 –0.5253 to 1.7673 0.2883
Continent 40 1.2655 –0.3051 to 2.8362 0.1143
Mean age 40 0.0503 0.0243 to 0.0762 0.0002a
Age range 40 0.0057 –0.0210 to 0.0325 0.6739
ED assessment method  40 1.5236 –0.1845 to 3.2316 0.0804
Cancer site 40 –1.8135 –2.5841 to –1.0429 <0.0001b
Age standard deviation  17 –0.0078 –0.0733 to 0.0576 0.8144
Proportion of patients who  15 1.0584 –1.0225 to 3.1393 0.3188 
underwent radiotherapy
Proportion of patients 12 –3.6361 –19.1360 to 11.8639 0.6457 
with diabetes
Proportion of patients who 12 0.1348 –1.9925 to 2.2621 0.9012 
underwent chemotherapy
aSignificance code controlling for type I error rate <0.05 and >0.01. bSignificance code controlling for type I error rate 
<0.0001. CI = confidence interval. ED = erectile dysfunction. MA = meta-analysis.
of diagnosis and 42.70% (95% CI = 32.97% 
to 53.03%) after treatment, across 
cancer locations. A high degree of overall 
heterogeneity (I 2 = 98%; P<0.001) was 
found. Figure 3 shows the prevalence of ED 
among patients with cancer.
To locate the potential predictors that 
account for the very high heterogeneity of ED 
prevalence among all the primary studies 
involving patients with cancer in the two 
treatment stages, MA regression analyses 
were conducted, with 10 predictors used. 
Distribution plots of study counts for each 
of the 10 possible predictors are shown in 
Supplementary Figure S2. Study counts 
of these 10 possible predictors for the ED 
prevalence among patients with cancer 
and P-values for continuous predictor (or 
smallest P-value for the dummy variables 
of categorical predictor) in the univariate MA 
regression analysis are shown in Table 2. 
The results by the univariate MA regression 
showed that ‘mean age’ and ‘cancer site’ 
variables were significantly associated with 
the ED prevalence.
After a manual variable selection accounting 
for the multicollinearities of the predictors, 
a parsimonious MA regression model was 
built to predict the highly heterogeneous ED 
prevalence. Regression coefficient estimates 
of this prediction model are shown in Table 3. 
This model only included two predictors: 
stage and cancer site. Since both of these 
predictors are categorical variables, dummy 
variables were created to represent them. The 
reference level for stage was selected as ‘at 
diagnosis’, and the reference level for cancer 
site was selected as ‘prostate’, since prostate 
cancer has the highest count (n = 12) in the 
collected primary study data (this count is 
the same as for rectum cancer) and prostate 
cancer is a common cancer in urology. Both 
predictors are significantly controlling for 
an FDR <0.05 in this MA regression model, 
indicating that the ED prevalence estimates 
reported by primary studies were significantly 
associated with factors of stage and cancer 
site. The interpretations of those significant 
regression coefficients are given as follows: 
study-reported odds of ED at after-treatment 
stage are estimated to be 2.4823 (exponential 
of 0.9092) times that of at-diagnosis 
stage controlling for other covariates 
(95% CI = 1.3054 to 4.7204; adjusted P-value 
controlling for FDR = 0.0204); study-reported 
odds of ED for patients with colon cancer 
are estimated to be 0.2300 (exponential of 
–1.4697) times that of patients with prostate 
cancer controlling for other covariates 
(95% CI = 0.0697 to 0.7587; adjusted P-value 
controlling for FDR = 0.0434); study-reported 
odds of ED for patients with lymphoma cancer 
are estimated to be 0.2530 (exponential of 
–1.3744) times that of patients with prostate 
cancer controlling for other covariates 
(95% CI = 0.0756 to 0.8470; adjusted P-value 
controlling for FDR = 0.0473); study-reported 
odds of ED for patients with multiple cancers 
are estimated to be 0.1041 (exponential of 
–2.2625) times that of patients with prostate 
cancer controlling for other covariates 
(95% CI = 0.0419 to 0.2586; adjusted P-value 














































Heterogeneity: I 2 = 98%, τ2 = 1.4365, χ234 = 2117 (   = 0)
Random effects model
Heterogeneity: I 2 = 98%, τ2 = 1.4365, χ239 = 2299 (   = 0)
Residual heterogeneity: I 2 = 98%, χ238 = 2298 (   = 0) 
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Figure 3. Prevalence of ED among patients with cancer.
ED = erectile dysfunction. 
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odds of ED for patients with penis cancer 
are estimated to be 0.1725 (exponential of 
–1.7574) times that of patients with prostate 
cancer controlling for other covariates 
(95% CI = 0.0394 to 0.7553; adjusted P-value 
controlling for FDR = 0.0433); study-reported 
odds of ED for patients with testis cancer 
are estimated to be 0.1353 (exponential of 
–2.0001) times that of patients with prostate 
cancer controlling for other covariates 
(95% CI = 0.0730 to 0.2508; adjusted P-value 
controlling for FDR <0.0001).
The R 2 value of this MA regression is 
as high as 75.70%, indicating that this MA 
regression model already accounts for 
75.70% heterogeneity of ED prevalence 
reported by the 40 studies involving patients 
with cancer (data not shown). The back-
transformed estimated ED prevalence 
values for studies with patients of different 
cancers at the two stages by this MA 
regression are shown in Table 4.
DISCUSSION
Summary
In the present systematic review the search 
yielded 1301 individual studies, of which 43 
studies with a total of 13 148 participants 
were included in the analysis. The study 
provides pooled estimates for ED in 
survivors of cancer across all cancer sites, 
providing this kind of synthesised data for 
the first time. Overall, pooled data of the 
included studies showed an ED prevalence 
of 40.72% (95% CI = 31.80% to 50.29%) in 
patients with cancer, with a prevalence of 
28.60% (95% CI = 12.10% to 53.83%) at time 
of diagnosis and 42.70% (95% CI = 32.97% 
to 53.03%) after treatment, across cancer 
locations.
Erectile dysfunction was particularly high 
in male survivors of cancer and was found to 
be associated with cancer treatment, cancer 
site, and age.
Strengths and limitations
This systematic review and MA provide a 
comprehensive overview of evidence on ED 
prevalence in survivors of cancer in general, 
with studies using validated self-reported 
methods. 
Limitations of the present analysis 
include the inherent limitations from the 
included studies. Study populations were on 
average aged >60 years, which may have 
contributed to the prevalence as ED risks 
increase with age. This is similar to the over-
representation of cancer sites in the pelvic 
area. Again, because of the small number 
of primary studies that provided complete 
clinical and biological (for example, serum 
testosterone or oestradiol levels) features 
of the participants, the authors were not 
able to run some meta-regression analyses 
using well-known independent risk factors 
for ED (such as dyslipidaemia, hypertension, 
diabetes mellitus, and depression) as 
moderators of the present findings. Lastly, 
the results pertaining to survivors of cancer 
with multiple cancer sites need to be taken 
with caution given that there were only three 
primary studies that were included in the 
analysis. 
Comparison with existing literature
Meta-analyses of studies reporting ED 
prevalence levels in healthy males are rare 
and mostly focus on samples of Asian males. 
These studies report that ED prevalence 
in individual studies has been reported 
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Table 4. Back-transformed estimated ED prevalence values for 
studies with patients of different cancers at two stages by the 
predictive MA regression model
 Prevalence at diagnosis,  Prevalence at treatment,  
Cancer site % (95% CI) % (95% CI)
Prostate 59.2 (48.7 to 68.9) 78.3 (58.2 to 90.3)
Colon  25.0 (9.8 to 50.4) 45.3 (18.6 to 75.0)
Colorectal  79.1 (61.8 to 89.9) 90.4 (76.4 to 96.5)
Haematological  57.4 (37.0 to 75.5) 77.0 (53.9 to 90.5)
Lymphoma  26.8 (10.6 to 53.2) 47.6 (19.9 to 77.0)
Multiple 13.1 (6.3 to 25.2) 27.2 (11.8 to 51.2)
Penis 20.0 (5.7 to 50.7) 38.3 (11.6 to 74.6)
Anus  62.5 (21.6 to 91.0) 80.5 (37.9 to 96.6)
Rectum  49.9 (40.4 to 59.4) 71.2 (53.9 to 83.9)
Testis 16.4 (10.7 to 24.3) 32.7 (16.8 to 53.9)
CI = confidence interval. MA = meta-analysis.
Table 3. Prediction model for highly heterogeneous ED prevalence
Regression  Standard   Adjusted 
coefficients Estimate error z P-value P-value
Intercept –0.5380 0.2720 –1.9778 0.0479 0.0659
Stage: after treatment  0.9092 0.3279 2.7726 0.0056 0.0204a
Cancer site     
 Colon –1.4697 0.6089 –2.4136 0.0158 0.0434a
 Colorectal 0.9628 0.4856 1.9830 0.0474 0.0744
 Haematological –0.0742 0.4759 –0.1560 0.8761 0.9637
 Lymphoma –1.3744 0.6165 –2.2293 0.0258 0.0473a
 Multiple –2.2625 0.4643 –4.8726 <0.0001 <0.0001b
 Penis –1.7574 0.7535 –2.3324 0.0197 0.0433a
 Anus 0.1397 0.9449 0.1478 0.8825 0.8825
 Rectum –0.3761 0.2919 –1.2888 0.1975 0.2414
 Testis –2.0001 0.3148 –6.3533 <0.0001 <0.0001b
aSignificance code controlling for false discovery rate (FDR) <0.05 and >0.01. bSignificance code controlling for FDR 
<0.0001. ED = erectile dysfunction.
from 2% to 82%, differing among age 
groups and how ED has been assessed. 
Generally, lowest reports have been found 
among younger males aged between 20 
and 29 years at 15.1% (99% CI = 12.2% to 
18.1%), while the highest have been found 
in the groups aged ≥60 years at 70.0% 
(99% CI = 62.3% to 77.7%).60 Studies have 
noted that self-reporting leads to lower 
estimates than measuring by a standardised 
questionnaire.61,62 Overall pooled estimate for 
ED prevalence has been reported at 49.69% 
(95% CI = 39.29% to 60.10%) for Chinese 
samples.63
Most studies included in the presented 
MA focused on cancers located in the pelvic 
region (prostate and rectum) and testis, 
where the effects would be expected to be 
strongest given the possible neurovascular 
damage associated with treatment. 
Androgen-deprivation therapy (ADT), which 
is used in prostate cancer management, 
leads to ED in most males who did not 
have dysfunction before therapy.64–66 Various 
chemotherapeutic agents may induce micro-
angiopathy and vascular insufficiency in the 
corpus cavernosum of the penis as well 
as neurotoxicity that may result in ED.67 In 
a study of >260 males on platinum-based 
chemotherapy, 40% were reported to have 
ED on standardised questionnaires, which 
corresponds to pooled data in the present 
analysis.68 Erectile dysfunction is also 
a common finding after radiation therapy 
for prostate cancer with varying incidence 
reported in studies depending on dose, 
technique, associated treatments, and time 
post-treatment, with brachytherapy showing 
lower rates of ED compared with external-
beam radiation therapy in some studies.69,70
Surgical cancer treatment in the pelvic 
area may also lead to post-operative sexual 
dysfunction, depending both on the surgical 
techniques and methods used in assessing 
ED post-operatively. In one study, >90% 
of patients who had radical prostatectomy 
reported lower scores on the IIEF-5 than 
before surgery,71 with an Italian-based 
study reporting that reaching perioperative 
levels does not equal patient satisfaction, 
with little over 25% of patients who reported 
preoperative scores being satisfied. 
Only males who achieved scores >22, as 
measured by the IIEF-5, and who returned 
to the same levels post-operatively were 
also satisfied with their sexual function.72 
Similarly, 86% of males who had radical 
cystectomy were not able to achieve vaginal 
penetration73 and studies report between 10% 
and 50% of males having sexual dysfunction 
following colorectal surgery, where the 
proposed mechanism may lie in the injury 
to the hypogastric plexus.43,74 In survivors 
of testicular cancer, a study measuring 
blood flow and erectile haemodynamic 
using duplex ultrasonography reported that 
12 months after treatment there were no 
differences between males with or without 
hypogonadism, suggesting hyperadrenergic 
mediated causes of ED.75 
Sexual function may be influenced by 
systemic chemo- or radiotherapy, as 
well as by psychological factors, such as 
depression, anxiety, low self-esteem, or 
issues with body image, which are known 
conditions in all patients with cancer 
and survivors, regardless of the primary 
cancer site.18,76–81 However, very few studies 
examine the effects of cancer sites outside 
of the pelvic area on overall sexual function 
or ED, specifically, in males. An MA on 
sexual functioning in male lymphoma 
survivors reported prevalence of sexual 
dysfunction between 20% and 54%.82 
Anecdotal evidence also suggests similar 
prevalence in patients with lung cancer. 
In fact, though this is the most prevalent 
cancer in males globally, to the authors' 
knowledge there is still no research on 
sexual function in male patients with lung 
cancer or survivors, as most of the focus 
is on short-term survival rather than post-
treatment quality of life.83 
Implications for practice
The present analysis has shown high 
prevalence of ED in survivors of cancer at 
various points and across cancer types. The 
aetiology of ED in survivors of cancer is 
multimodal with a variety of factors, including 
psychological and physical ones. The results 
should improve the visibility of this issue and 
allow healthcare professionals to more easily 
identify survivors of cancer under higher risk 
of ED. Moreover, it is important that clinicians 
be aware of the impact of ED on the quality 
of life and mental health of survivors of 
cancer, especially as sexuality and intimacy 
may reduce some of the psychosocial 
issues associated with receiving a cancer 
diagnosis.19,20 Various therapeutic modalities 
exist and healthcare providers should facilitate 
an open exchange with patients before 
cancer treatment and manage expectations. 
Primary care physicians are of great 
importance here given their role in follow-
through during cancer care and beyond. As 
males are generally less prone to discuss 
sexual health problems in a clinical setting, 
clinicians should routinely and proactively 
ask about sexual health, recognising and 
acknowledging any concerns. This approach 
may increase patient satisfaction and improve 
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